Fidelis Capital Partners LLC Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fidelis Capital Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 364 shares of the biopharmaceutical company’s stock, valued at approximately $320,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Markel Corp grew its position in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock worth $56,083,000 after purchasing an additional 1,000 shares during the period. Cibc World Market Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock valued at $4,481,000 after acquiring an additional 86 shares during the period. Blair William & Co. IL grew its position in shares of Regeneron Pharmaceuticals by 18.4% during the 1st quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock valued at $999,000 after acquiring an additional 222 shares during the period. Sequoia Financial Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 23.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 93 shares during the period. Finally, Baird Financial Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 100.9% during the 1st quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock valued at $25,513,000 after acquiring an additional 18,345 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last three months, insiders sold 13,729 shares of company stock valued at $13,124,641. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $896.82 on Friday. The company has a market cap of $98.43 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. The company has a fifty day simple moving average of $953.01 and a two-hundred day simple moving average of $891.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $10.96 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on REGN. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. UBS Group raised their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $976.41.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.